Document Detail

Clinical aspects of antenatal glucocorticoid treatment for prevention of neonatal respiratory distress syndrome.
MedLine Citation:
PMID:  3443899     Owner:  NLM     Status:  MEDLINE    
Main indications for antenatal administration glucocorticoid to pregnant women are premature contractions, hemorrhage during pregnancy, conditions of fetal distress and maternal diseases. There are some absolute or relative contraindications as well: severe forms of preeclampsia, diabetes mellitus, premature rupture of membranes, maternal and/intrauterine infections. In a retrospective evaluation of the data obtained at our institution of 637 nonrandomized cases from the years 1980-1985, we could demonstrate the dependence of the therapeutic results on the sex of the newborn. The RDS incidence is significantly different after betamethasone prophylaxis. It was 1/25 (4%) in girls compared to 13/31 (42%) in boys. A marked reduction of the RDS incidence is only detectable after betamethasone therapy from the 32nd to the 34th week of gestation. Thus we recommend RDS prophylaxis for all patients with premature contraction, mainly between the 32nd and 34th week of pregnancy. In addition, it should be given in cases of confirmed lung immaturity. Special restrictions are necessary in cases of preeclampsia, eclampsia, diabetes and confirmed maternal infections. In the group of diabetes or preeclampsia patients an RDS prophylaxis should only be given, if at all, when it can be performed under intensive care conditions.
H K Weitzel; U Lorenz; B Kipper
Related Documents :
15954869 - Period of gestational diabetes mellitus diagnosis and maternal and fetal morbidity.
23908009 - Maternal bisphenol a exposure during pregnancy and its association with adipokines in m...
24942869 - Prenatal vitamin intake during pregnancy and offspring obesity.
16490519 - Optical coherence tomography in the management of acute retinopathy of prematurity.
9542269 - Should we treat minor degrees of glucose intolerance in pregnancy?
23003679 - Association of breastfeeding and exposure to maternal smoking during pregnancy with chi...
19246429 - Polymorphisms in metabolic genes cyp1a1 and gstm1 and changes in maternal smoking durin...
2358199 - Congenital factor xiii deficiency with treatment of factor xiii concentrate and normal ...
603799 - Noradrenaline appearance in guinea pig brown adipose tissue. its significance in neonat...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of perinatal medicine     Volume:  15     ISSN:  0300-5577     ISO Abbreviation:  J Perinat Med     Publication Date:  1987  
Date Detail:
Created Date:  1988-05-06     Completed Date:  1988-05-06     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  0361031     Medline TA:  J Perinat Med     Country:  GERMANY, WEST    
Other Details:
Languages:  eng     Pagination:  441-6     Citation Subset:  IM    
Department for Obstetrics and Gynecology, Free University of Berlin, West Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Betamethasone / therapeutic use*
Dexamethasone / therapeutic use*
Embryonic and Fetal Development / drug effects
Infant, Newborn
Lung / drug effects,  embryology*
Respiratory Distress Syndrome, Newborn / prevention & control*
Reg. No./Substance:
378-44-9/Betamethasone; 50-02-2/Dexamethasone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Consequences of asphyxia in surfactant deficiency.
Next Document:  Natural surfactant substitution in respiratory distress syndrome.